{"id":"W4387824903","doi":"10.1016/j.annonc.2023.09.1436","title":"1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; INCLIVA Instituto de Investigación Sanitaria; Deutschen Konsortium für Translationale Krebsforschung; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Universidad de Navarra; Seoul National University Hospital; Fundación Científica Asociación Española Contra el Cáncer; Sanofi; Sungkyunkwan University; Pfizer; Incyte; Yonsei University; Seagen; BeiGene; University of Seoul; Cancer Research UK; Azərbaycan Milli Elmlər Akademiyası; Mirati Therapeutics; F. Hoffmann-La Roche; National Cancer Center Japan; Les Laboratories Pierre Fabre; Array BioPharma; Taiho Pharmaceutical; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncode Institute; American Society of Clinical Oncology; Merck; Universitat de Barcelona; Amgen; Celgene","keywords":"Ramucirumab; Medicine; Paclitaxel; Trastuzumab; Internal medicine; Oncology; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005346219,0.0001835375,0.0007187451,0.0002832987,0.00007659391,0.000008923792,0.0001242847,0.00009875607,0.00006637418],"category_scores_gemma":[0.0002659065,0.0001667878,0.0001040367,0.0004135819,0.00009053851,0.0001264437,0.0001058783,0.0001081795,0.000001148914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005993608,"about_ca_system_score_gemma":0.0001799536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001293568,"about_ca_topic_score_gemma":0.0003587985,"domain_scores_codex":[0.9982679,0.00006879532,0.0007104959,0.0003815723,0.0002383119,0.0003329382],"domain_scores_gemma":[0.9985599,0.0003648964,0.0003923276,0.0002930442,0.0002726519,0.0001171995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05793228,0.02703413,0.05954665,0.00119459,0.004804898,0.0003634288,0.04635793,0.02397869,0.00297748,0.0005448021,0.1756222,0.5996429],"study_design_scores_gemma":[0.2480634,0.1960704,0.4428685,0.0004557088,0.002681055,0.00001967562,0.03614562,0.02951519,0.002783612,0.00047894,0.04006451,0.0008533411],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916081,0.0002461492,0.0003325049,0.005247062,0.0002543028,0.001449188,0.0004534114,0.00005157736,0.0003577246],"genre_scores_gemma":[0.996333,0.0005358052,0.001026718,0.0004736829,0.0002177495,0.0001853474,0.00029456,0.00002597011,0.000907168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5987896,"threshold_uncertainty_score":0.6801409,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139977458540278,"score_gpt":0.4384518013909765,"score_spread":0.3244540555369487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}